RESMED ($RMD) posted quarterly earnings results for Q1 2027 on Thursday, October 29th. The company reported earnings of $2.91 per share, beating estimates of $2.70 by $0.21. The company also reported revenue of $1,414,810,000, beating estimates of $1,405,993,396 by $8,816,604.
You can see Quiver Quantitative's $RMD stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
RESMED Insider Trading Activity
RESMED insiders have traded $RMD stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $RMD stock by insiders over the last 6 months:
- MICHAEL J. FARRELL (Chairman and CEO) has made 0 purchases and 5 sales selling 24,955 shares for an estimated $5,325,259.
- PETER C FARRELL has made 0 purchases and 2 sales selling 8,970 shares for an estimated $2,027,688.
- MICHAEL J RIDER (Global General Counsel) sold 400 shares for an estimated $102,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
RESMED Hedge Fund Activity
We have seen 393 institutional investors add shares of RESMED stock to their portfolio, and 495 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,222,473 shares (+inf%) to their portfolio in Q2 2026, for an estimated $238,235,538
- JPMORGAN CHASE & CO added 833,536 shares (+inf%) to their portfolio in Q2 2026, for an estimated $162,439,495
- MORGAN STANLEY removed 757,890 shares (-28.2%) from their portfolio in Q2 2026, for an estimated $147,697,603
- FIRST TRUST ADVISORS LP added 740,871 shares (+48.2%) to their portfolio in Q2 2026, for an estimated $144,380,940
- BANK OF NEW YORK MELLON CORP removed 727,776 shares (-14.8%) from their portfolio in Q2 2026, for an estimated $141,828,986
- DEKABANK DEUTSCHE GIROZENTRALE added 715,812 shares (+2242.3%) to their portfolio in Q3 2026, for an estimated $158,266,033
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 679,489 shares (+150.9%) to their portfolio in Q2 2026, for an estimated $132,418,816
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
RESMED Price Targets
Multiple analysts have issued price targets for $RMD recently. We have seen 5 analysts offer price targets for $RMD in the last 6 months, with a median target of $266.0.
Here are some recent targets:
- Nathan Treybeck from Wells Fargo set a target price of $225.0 on 07/08/2026
- Craig Wong-Pan from RBC Capital set a target price of $276.0 on 07/08/2026
- Justin Patterson from Keybanc set a target price of $266.0 on 06/22/2026
- David Bailey from Morgan Stanley set a target price of $230.0 on 06/17/2026
- Laura Sutcliffe from Citigroup set a target price of $270.0 on 06/15/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
